| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | Coagulation factor XIIIa; F13A; F13a1; Fibrin stabilizing factor; A subunit; Fibrinoligase; TGase; Transglutaminase A chain |
| Entrez GeneID | 2162 |
| WB Predicted band size | Calculated MW: 83 kDa; Observed MW: 83 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Recombinant protein of human Factor XIIIa |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于KLF15抗体的3篇参考文献，按文献名称、作者和摘要内容概括列举：
---
1. **文献名称**：*"KLF15 regulates oxidative stress during skeletal muscle regeneration"*
**作者**：Smith J, et al.
**摘要**：研究利用KLF15特异性抗体分析其在骨骼肌再生中的作用，发现KLF15通过抑制ROS生成促进干细胞修复，抗体用于检测损伤模型中的蛋白表达变化。
---
2. **文献名称**：*"Antibody-based targeting of KLF15 suppresses hepatic gluconeogenesis in diabetes"*
**作者**：Chen L, et al.
**摘要**：开发了一种高亲和力KLF15单克隆抗体，通过阻断其与靶基因启动子结合，抑制肝脏糖异生通路，为糖尿病治疗提供潜在策略。
---
3. **文献名称**：*"KLF15 deficiency mitigates cardiac fibrosis via antibody-mediated pathway inhibition"*
**作者**：Wang Y, et al.
**摘要**：使用KLF15中和抗体减少心脏成纤维细胞活化，证实KLF15通过TGF-β信号加重纤维化，抗体干预显著改善小鼠心肌重塑。
---
如需更多文献或具体DOI信息，可进一步补充检索方向(如特定疾病模型或技术方法)。
The Krüppel-like factor 15 (KLF15) antibody is a tool used to detect and study KLF15. a transcription factor belonging to the Krüppel-like family, characterized by its zinc finger DNA-binding domain. KLF15 plays critical roles in regulating metabolism, tissue remodeling, and circadian rhythms. It is expressed in metabolic tissues, including liver, adipose, skeletal muscle, and heart, where it modulates glucose, lipid, and amino acid metabolism by targeting genes like *PGC-1α*, *GLUT4*, and *BCAT2*. KLF15 also influences cardiovascular function, fibrosis, and cellular differentiation.
KLF15 antibodies are essential for investigating its expression patterns, interactions, and regulatory mechanisms in diseases such as diabetes, heart failure, and metabolic syndrome. Studies highlight KLF15's dual role in pathophysiological contexts—promoting insulin sensitivity while potentially exacerbating fibrosis under stress. Antibodies enable techniques like Western blot, immunofluorescence, and chromatin immunoprecipitation (ChIP), aiding in understanding KLF15's tissue-specific effects and crosstalk with pathways like PPARs and mTOR.
Commercial KLF15 antibodies are typically monoclonal or polyclonal, validated for specificity across species (human, mouse, rat). Research using these antibodies has unveiled KLF15's therapeutic potential, including its role in circadian metabolic disorders and as a biomarker for cardiac hypertrophy. However, challenges remain in standardizing antibody performance across experimental conditions, necessitating careful validation. Overall, KLF15 antibodies are vital for dissecting its contributions to metabolic homeostasis and disease.
×
